Halozyme Therapeutics (NASDAQ:HALO) announced on Thursday its plans to acquire German drug developer Evotec SE ADR (NASDAQ:EVO) in a deal valued at approximately 2 billion euros ($2.10 billion), to ...

German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics , Bloomberg News reported on Thursday.

Halozyme intends to purchase all the shares of Evotec at 11 euros per share, which represents a premium of 27.5% to Evotec's last close price. U.S.-listed shares of Evotec were up 6.3%, while those of ...

Germany-based Evotec SE (NASDAQ:EVO) is trading on Monday after a report that suggests the company is a takeover target. The ...

Evotec listed three investors with stakes of 5% or greater in its 2023 annual report. At that time, T. Rowe Price was the ...

Also Read: Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development According to the report, the investment firm has been trying to meet with senior Evotec executives as it looks ...

Shares in Evotec jumped as much as 13.3% on Monday after regulatory filings showed private equity firm Triton had built an over 9% stake in the German drug development company.

Evotec's other major shareholders are Novo Nordisk parent Novo Holdings and Mubadala Investment. Triton's other investments range from pharmaceutical companies Bormioli Pharma and Clinigen to tank ...

Q3 2024 Earnings Call Transcript November 6, 2024 Evotec SE misses on earnings expectations. Reported EPS is $-0.12 EPS, ...

Any significant move would also need support from Evotec's other major shareholders Novo Holdings - the parent company of drugmaker Novo Nordisk - and Abu Dhabi sovereign fund Mubadala Investment ...

FRANKFURT: Europe’s main stock index logged its best day in six weeks on Monday, with defence stocks in the lead ...